Double-stranded RNAs (dsRNAs) longer than 30 bp have not been considered desirable RNA interference (RNAi) triggering structures in mammalian cells as they nonspecifically activate innate immune response. However, in earlier studies, not only dsRNA length but also 5′-triphosphate moiety produced by in vitro transcription might have affected the stimulation of innate immune system. Herein, using chemically synthesized long dsRNAs without 5′-triphosphate, we elucidated direct relationship between length of dsRNAs and innate immune stimulation. First, we found that blunt-ended, chemically synthesized 38/40–60 bp-long dsRNAs induced retinoic acid-inducible gene I (RIG-I)-mediated innate immune response, which was suppressed by the introduction of the 2-nt 3′ overhang structure. Surprisingly, we discovered that RIG-I activation by these long dsRNAs is also sequence dependent, and the sequence composition at dsRNA termini is important for RIG-I activation. In addition, we identified that long dsRNAs over 38 bp could elicit single- or dual-target gene silencing in a Dicer-independent manner. Taken together, our findings may serve as guidelines to develop an immunostimulatory RNAi trigger to exploit host's innate immune system, as well as a specific dual-gene targeting RNAi therapeutics platform without nonspecific innate immune stimulation by RIG-I.
Get full access to this article
View all access options for this article.
References
1.
FireA, XuS, MontgomeryMK, KostasSA, DriverSE and MelloCC. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391:806–811.
ChangC, KimH, DuaP, KimS, LiCJ and LeeD. (2011). Structural diversity repertoire of gene silencing small interfering RNAs. Nucleic Acid Ther, 21:125–131.
4.
KimDH, BehlkeMA, RoseSD, ChangM-S, ChoiS and RossiJJ. (2005). Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol, 23:222–226.
5.
BernsteinE, CaudyAA, HammondSM and HannonGJ. (2001). Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 18:363–366.
6.
WilsonRC and DoudnaJA. (2013). Molecular mechanisms of RNA interference. Annu Rev Biophys, 42:217–239.
7.
HungY-H and SlotkinRK. (2021). The initiation of RNA interference (RNAi) in plants. Curr Opin Plant Biol, 61:102014.
8.
BellésX. (2010). Beyond drosophila: RNAi in vivo and functional genomics in insects. Annu Rev Entomol, 55:111–128.
9.
DangY, YangQ, XueZ and LiuY. (2011). RNA interference in fungi: pathways, functions, and applications. Eukaryot Cell, 10:1148–1155.
10.
ElbashirSM, HarborthJ, LendeckelW, YalcinA, WeberK and TuschlT. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411:494–498.
11.
WuSY, Lopez-BeresteinG, CalinGA and Sood.AK (2014). RNAi therapies: drugging the undruggable. Sci Transl Med, 6:240ps7.
12.
LedfordH. (2018). Gene-silencing technology gets first drug approval after 20-year wait. Nature, 560:291–293.
13.
Scott LJ. (2020). Givosiran: first approval. Drugs, 80:335–339.
14.
ShahRJ, PanS, LanierGM, MellelaL, AronowWS and Jain.D (2021). Recent advances in the pharmacotherapy of TTR amyloidosis of the heart. Vessel plus, 5:53.
15.
Lamb YN. (2021). Inclisiran: first approval. Drugs, 81:1–7.
16.
KimY, KangYG, ChoeJY, LeeD, ShinC, HongSW and LeeD. (2018). RNA interference-mediated gene silencing by branched tripodal RNAs does not require dicer processing. Nucleic Acid Ther, 28:44–49.
17.
KhaledA, GuoS, LiF and GuoP. (2005). Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett, 5:1797–1808.
18.
GrimmD and KayMA. (2007). Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol Ther, 15:878–888.
19.
SledzCA, HolkoM, VeerMJ, SilvermanRH and WilliamsBRG. (2003). Activation of the interferon system by short-interfering RNAs. Nat Cell Biol, 5:834–839.
20.
BridgeAJ, PebernardS, DucrauxA, NicoulzaA-L and IggoR. (2003). Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet, 34:263–264.
21.
JudgeAD, SoodV, ShawJR, FangD, McClintockK and MacLachlanI. (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol, 23:457–462.
KleinmanME, YamadaK, TakedaA, ChandrasekaranV, NozakiM, BaffiJZ, AlbuquerqueRJC, YamasakiS, ItayaM, et al. (2008). Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature, 452:591–597.
24.
MansooriB, MohammadiA, JangSS and BaradaranB. (2016). Mechanisms of immune system activation in mammalians by small interfering RNA (siRNA). Artif Cells Nanomed Biotechnol, 44:1589–1596.
25.
HurS. (2019). Double-stranded RNA sensors and modulators in innate immunity. Annu Rev Immunol, 37:349–375.
26.
MancheL, GreenSR, SchmedtC and MathewsMB. (1992). Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol Cell Biol, 12:5238–5248.
27.
TaylorSS, HasteNM and GhoshG. (2005). PKR and eIF2alpha: integration of kinase dimerization, activation, and substrate docking. Cell, 23:823–825.
28.
LiuL, BotosI, WangY, LeonardJN, ShiloachJ, SegalDM and DaviesDR. (2008). Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science, 320:379–381.
29.
AlexopoulouL, HoltAC, MedzhitovR and FlavellRA. (2001). Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature, 413:732–738.
30.
LeonardJN, GhirlandoR, AskinsJ, BellJK, MarguliesDH, DaviesDR and SegalDM. (2008). The TLR3 signaling complex forms by cooperative receptor dimerization. Proc Natl Acad Sci U S A, 105:258–263.
31.
BrisseM and Ly.H (2019). Comparative structure and function analysis of the RIG-I-like receptors: RIG-I and MDA5. Front Immunol, 10:1586.
32.
KatoH, TakeuchiO, Mikamo-SatohE, HiraiR, KawaiT, MatsushitaK, HiiragiA, DermodyTS, FujitaT and AkiraS. (2008). Length-dependent recognition of double stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med, 205:1601–1610.
33.
HornungV, EllegastJ, KimS, BrzózkaK, JungA, KatoH, PoeckH, AkiraS, ConzelmannKK, et al. (2006). 5'-Triphosphate RNA is the ligand for RIG-I. Science 314:. 994–997.
34.
TakahasiK, YoneyamaM, NishihoriT, HiraiR, KumetaH, NaritaR, GaleM, InagakiF and FujitaT. (2008). Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol Cell, 29:428–440.
35.
MarquesJ, DevosseT, WangD, Zamanian-DaryoushM, SerbinowskiP, HartmannR, FujitaT, BehlkeMA and WilliamsBRG. (2006). A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol, 24:559–565.
36.
LuC, XuH, Ranjith-KumarCT, BrooksMT, HouTY, HuF, HerrAB, StrongRK, KaoCC and LiP. (2010). The structural basis of 5′ triphosphate double-stranded RNA recognition by RIG-I C-terminal domain. Structure, 18:1032–1043.
37.
ChangCI, KangHS, BanC, KimS and LeeD. (2009). Dual-target gene silencing by using long, synthetic siRNA duplexes without triggering antiviral responses. Mol Cells, 27:689–695.
38.
AlbertsB, JohnsonA, LewisJ, RaffM, RobertsK and WalterP. (2002). Innate Immunity, Molecular Biology of the Cell, 4th edn. Garland Science, New. York.
39.
ThoresenD, WangW, GallsD, GuoR, XuL and PyleAM. (2021). The molecular mechanism of RIG-I activation and signaling. Immunol Rev, 00:1–15.
40.
RenX, LinehanMM, IwasakiA and PyleAM. (2019). RIG-I recognition of RNA targets: the influence of terminal base pair sequence and overhangs on affinity and signaling. Cell Rep, 29:3807–3815.
SaitoT, OwenDM, JiangF, MarcotrigianoJ and Gale JrM. (2008). Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature, 454:523–527.
45.
DavisWG, BowzardJB, SharmaSD, WiensME, RanjanP, GangappaS, StuchlikO, PohlJ, DonisRO, et al. (2012). The 3′ untranslated regions of influenza genomic sequences are 5′ PPP-independent ligands for RIG-I. PLoS One, 7:e32661.
46.
BinderM, EberleF, SeitzS, MückeN, HüberCM, KianiN, KaderaliL, LohmannV, DalpkeA, et al. (2011). Molecular mechanism of signal perception and integration by the innate immune sensor retinoic acid-inducible gene-I (RIG-I). J Biol Chem, 286:27278–27287.
47.
EllermeierJ, WeiJ, DuewellP, HovesS, StiegMR, AdunkaT, NoerenbergD, AndersH-J, MayrD, et al. (2013). Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res, 73:1709–1720.
48.
SinghN, RanjanP, CaoW, PatelJ, GangappaS, DavidsonBA, SullivanJM, PrasadPN, KnightPR, et al. (2020). A dual-functioning 5′-PPP-NS1shRNA that activates a RIG-I antiviral pathway and suppresses influenza NS1. Mol Ther Nucleic Acids, 19:1413–1422.
49.
Mattes WB. (2020). In vitro to in vivo translation. Curr Opin Toxicol, 23:114–118.
50.
VessillierS, EastwoodD, FoxB, SathishJ, SethuS, DougallT, ThorpeSJ, ThorpeR and StebbingsR. (2015). Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials—whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm. J Immunol Methods, 424:43–52.
51.
StebbingsR, FindlayL, EdwardsC, EastwoodD, BirdC, NorthD, MistryY, DilgerP, LiefoogheE, et al. (2007). “Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol, 179:3325–3331.
52.
VessillierS, FortM, O'DonnellL, HintonH, NadwodnyK, PiccottiJ, RigsbyP, StaflinK, StebbingsR, et al. (2020). Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms—report of an international collaborative study. Cytokine, 2:100042.
53.
LingelA, SimonB, IzaurraldeE and SattlerM. (2004). Nucleic acid 3′-end recognition by the Argonaute2 PAZ domain. Nat Struct Mol Biol, 11:576–577.
54.
SanoM, SierantM, MiyagishiM, NakanishiM, TakagiY and SutouS. (2008). Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection. Nucleic Acids Res, 36:5812–5821.
55.
GvozdevaOV, DovydenkoIS, VenyaminovaAG, ZenkovaMA, VlassovVV and ChernolovskayaEL. (2014). 42-and 63-bp anti-MDR1-siRNAs bearing 2′-OMe modifications in nuclease-sensitive sites induce specific and potent gene silencing. FEBS Lett, 588:1037–1043.
56.
PoeckH, BeschR, MaihoeferC, RennM, TormoD, MorskayaSS, KirschnekS, GraffalE, LandsbergJ, et al. (2008). 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med, 14:1256–1263.
57.
KimMJ, KimH, GaoX, RyuJH, YangY, KwonIC, RobertsTM and KimSH. (2021). Multi-targeting siRNA nanoparticles for simultaneous inhibition of PI3K and Rac1 in PTEN-deficient prostate cancer. J Ind Eng Chem, 99:196–203.
58.
KunzeD, WuttigD, FuesselS, KraemerK, KotzschM, MeyeA, GrimmM-O, HakenbergOW and WirthMP. (2008). Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-XL) in bladder cancer cells. Anticancer Res, 28:2259–2263.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
